Urinary Urgency Articles & Analysis
11 news found
Lisa has a Bachelor of Science degree in Communication from Emerson University in Boston and an M.B.A. from the University of California, Irvine. About Overactive Bladder and Urinary Urgency Incontinence: According to the American Urological Association, OAB is a chronic, debilitating condition affecting over 33 million Americans. Urgency ...
The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system designed to treat overactive bladder (OAB) for patients with urinary urgency incontinence (UUI) symptoms. The system is the first sacral neuromodulation (SNM) device that offers a minimally invasive option, which may allow for a better patient experience and greater ...
He participated in the pivotal Medtronic trial, which led to InterStim’s original approval for the indication of urinary urge incontinence (UUI) in 1997. He was the national principal Investigator for the Medtronic InSite trial which demonstrated superior success of sacral neuromodulation when compared to standard medical therapy and the durability of sacral neuromodulation ...
Lisa has a Bachelor of Science degree in Communication from Emerson University in Boston and an M.B.A. from the University of California, Irvine. About Overactive Bladder and Urinary Urgency Incontinence: According to the American Urological Association, OAB is a chronic, debilitating condition affecting over 33 million Americans. Urgency ...
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021. ...
Bluewind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021. ...
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in ...
The proceeds will fund the company’s SANS-UUI pivotal clinical study of its miniaturized implantable neuromodulation technology platform for use in subjects with Urinary Urgency Incontinence, a symptom of overactive bladder (OAB). ...
The RENOVA iStim system is an investigational device designed to reduce urinary urge leakage and improve OAB symptoms. Overactive bladder or OAB, affects millions of women of all ages, and can negatively impact nearly every aspect of daily life—from work performance to family life, to social interactions. ...
The OverActive Bladder Stimulation System Study (OASIS), a prospective, interventional, multi-center study, will evaluate the safety and efficacy of RENOVA to improve urinary urgency incontinence (UUI) episodes. The OASIS study will enroll approximately 200 subjects at 15 study sites in the U.S. and sites in Europe. ...
Common symptoms include bloating, pelvic and/or abdominal pain, difficulty eating or feeling full quickly and urinary symptoms (urgency or frequency). If a woman is experiencing these symptoms for two or more weeks, and if they are new and unusual for her, she should see her doctor, according to OCRF. ...